Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study: can a common painkiller tame back pain in spondyloarthritis?

NCT ID NCT07582146

Symptom relief Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a drug called acemetacin can reduce pain and control disease activity in adults with active axial spondyloarthritis, a type of inflammatory arthritis that mainly affects the spine. About 150 people aged 18 to 65 will take a daily pill for 4 weeks. Researchers will measure pain levels, disease activity, and any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects who fully understand the purpose and procedures of the trial and voluntarily sign the Informed Consent Form (ICF); * Subjects aged 18-65 years (inclusive), regardless of gender; * Meet the 2025 ASAS-SPARTAN Revised Classification Criteria for Axial Spondyloarthritis; * ASDAS score \> 2.1. Exclusion Criteria: * Subjects with known allergy to acemetacin, other NSAIDs, or any excipients; * Subjects with active gastrointestinal ulcer/bleeding, or a history of recurrent ulcer/bleeding; * Subjects with severe cardiac or renal dysfunction, or hepatic dysfunction; * Subjects with ulcerative colitis or Crohn's disease; * Subjects who received systemic glucocorticoids or intra-articular glucocorticoid injections within 3 months prior to the study start; * Subjects who received targeted therapy within 3 months prior to the study start; * Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ankylosing spondylitis (AS) / radiographic axial spa (R-axspa) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis Axial Spondyloarthritis Non-Radiographic Axial Spondyloarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ankylosing spondylitis (AS) / radiographic axial spa (R-axspa) Axial spondyloarthritis Axial spondyloarthritis, non-radiographic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Rheumatology and Immunology, the First Medical Center, Chinese PLA General Hospital

    Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.